Themis Medicare

When is the next results date for Themis Medicare?

No Upcoming Board Meetings

Who are in the management team of Themis Medicare?

As of March 2023, Themis Medicare's management team includes Rajneesh Anand, Vijay Gopi Kishan Agarwal, Hari Subramaniam, Reena S Patel, Sachin D Patel (CEO), Dinesh S Patel (Chairman), Manjul Sandhu, Bhaskar Vemban Iyer, Shishir Dalal, and Reena S Patel (Alternate Director), featuring a mix of executive and non-executive directors.

As of March 2023, the management team of Themis Medicare includes the following members:<BR><BR>1. Rajneesh Anand - Non-Executive & Non-Independent Director<BR>2. Vijay Gopi Kishan Agarwal - Independent Non-Executive Director<BR>3. Hari Subramaniam - Independent Non-Executive Director<BR>4. Reena S Patel - Non-Executive Director<BR>5. Sachin D Patel - Executive Director / Managing Director / CEO / Promoter<BR>6. Dinesh S Patel - Chairman & Independent Director<BR>7. Manjul Sandhu - Independent Non-Executive Director<BR>8. Bhaskar Vemban Iyer - Independent Non-Executive Director<BR>9. Shishir Dalal - Additional Director<BR>10. Reena S Patel - Alternate Director<BR><BR>This team comprises a mix of executive and non-executive directors, with various roles contributing to the governance and management of the company.

Has Themis Medicare declared dividend?

Themis Medicare Ltd has declared a 50% dividend, amounting to ₹0.5 per share, with an ex-date of July 12, 2024. While recent total returns show volatility with negative performance over the last 6 months and 1 year, longer-term returns have been more favorable.

Themis Medicare Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 0.5<BR>- Ex-date: Jul-12-2024<BR><BR>Dividend Yield: 0.36%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -53.28%, with a dividend return of 0%, resulting in a total return of -53.28%.<BR><BR>Over the past year, the price return was -35.38%, the dividend return was 0.23%, leading to a total return of -35.15%.<BR><BR>In the 2-year period, the price return was -7.2%, the dividend return was 3.84%, culminating in a total return of -3.36%.<BR><BR>For the 3-year period, the price return was 73.83%, with a dividend return of 14.40%, resulting in a total return of 88.23%.<BR><BR>In the last 4 years, the price return was 76.12%, the dividend return was 20.90%, which gives a total return of 97.02%.<BR><BR>Over the past 5 years, the price return was 299.5%, with a dividend return of 47.83%, leading to an impressive total return of 347.33%.<BR><BR>Overall, Themis Medicare has declared a dividend, but the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last 6 months and 1 year, while longer-term returns show a more favorable performance.

Who are the peers of the Themis Medicare?

Themis Medicare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Anuh Pharma, Lincoln Pharma, Wanbury, and Kwality Pharma. While Sun Pharma and Cipla show excellent management and growth, Themis Medicare has average management risk and below-average growth, with a 1-year return of -33.90%, significantly lower than Wanbury's 104.73%.

Peers: Themis Medicare's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Anuh Pharma, Lincoln Pharma., Wanbury, and Kwality Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Average management risk is found at Themis Medicare, Anuh Pharma, Lincoln Pharma., Wanbury, and Kwality Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Remus Pharma., while Below Average growth is noted for Themis Medicare, Divi's Lab., Torrent Pharma, Lincoln Pharma., and Kwality Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Divi's Lab., Anuh Pharma, and Lincoln Pharma., while Good capital structure is found at Themis Medicare and Torrent Pharma, and Below Average capital structure is noted for Wanbury.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wanbury at 104.73%, while Themis Medicare has the lowest at -33.90%. This indicates that Themis Medicare's return is significantly lower than that of Wanbury. Additionally, the six-month return is negative for Themis Medicare, Lincoln Pharma., and Sun Pharma.Inds.

What does Themis Medicare do?

Themis Medicare Ltd, established in 1969 and operating in the Pharmaceuticals & Biotechnology sector, reported net sales of 717 Cr and a net loss of 97 Cr for the quarter ending March 2025, with a market cap of INR 1,147 Cr. The company has a P/E ratio of 38.00 and a debt-equity ratio of 0.17.

Overview: <BR>Themis Medicare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Themis Medicare Limited was incorporated in 1969 as 'Themis Chemicals Limited'. The company underwent a name change to Themis Medicare Limited in 2001. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 717 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -97 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 1,147 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.17 <BR>Return on Equity: 7.41% <BR>Price to Book: 2.85<BR><BR>Contact Details: <BR>Address: Plot No 69 A GIDC Indl Estate, Vapi Valsad Gujarat : 396195 <BR>Tel: 91-260-2421675 <BR>Email: themis@themismedicare.com <BR>Website: http://www.themismedicare.com

Who are the top shareholders of the Themis Medicare?

The top shareholders of Themis Medicare include Vividhmargi Investments Pvt Ltd at 15.78%, individual investors with a collective 24.14%, and Anuj Anantrai Sheth as the highest public shareholder at 4.58%. Additionally, 13 foreign institutional investors hold a small portion of 0.1%, while mutual funds have no significant holdings.

The top shareholders of Themis Medicare include a mix of promoters and individual investors. The majority of the shares are held by promoters, with Vividhmargi Investments Pvt Ltd being the largest shareholder at 15.78%. Individual investors collectively hold 24.14% of the shares, while the highest public shareholder is Anuj Anantrai Sheth, who owns 4.58%. Additionally, there are 13 foreign institutional investors (FIIs) holding a small portion of 0.1%, and mutual funds have not reported any significant holdings.

How big is Themis Medicare?

As of 24th July, Themis Medicare Ltd has a market capitalization of 1,113.00 Cr, with recent net sales of 405.51 Cr and a net profit of 29.83 Cr. The company reported shareholder's funds of 377.67 Cr and total assets of 566.42 Cr for the annual period ending March 2024.

As of 24th July, Themis Medicare Ltd has a market capitalization of 1,113.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Themis Medicare reported Net Sales of 405.51 Cr and a Net Profit of 29.83 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had Shareholder's Funds amounting to 377.67 Cr and Total Assets of 566.42 Cr.

Is Themis Medicare overvalued or undervalued?

As of August 4, 2025, Themis Medicare's valuation has shifted from attractive to risky due to significant overvaluation indicated by a negative PE ratio of -103.96 and poor stock performance, with a year-to-date return of -60.97%, contrasting unfavorably with peers like Sun Pharma and Cipla.

As of 4 August 2025, Themis Medicare's valuation grade has moved from attractive to risky, indicating a significant deterioration in its market position. The company is currently overvalued based on its financial ratios, which include a PE ratio of -103.96, an EV to EBITDA of 103.48, and a Price to Book Value of 2.34. These figures suggest that the company's earnings are not only negative but also that it is trading at a substantial premium relative to its book value.<BR><BR>In comparison to its peers, Themis Medicare's valuation stands out unfavorably; for instance, Sun Pharma has a PE ratio of 34.25 and an EV to EBITDA of 23.19, while Cipla shows a more attractive PE of 22.7 and an EV to EBITDA of 15.96. The stark contrast in these ratios highlights Themis Medicare's overvaluation in the current market. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -60.97%, significantly underperforming the Sensex, which has gained 3.69% in the same period.

How has been the historical performance of Themis Medicare?

Themis Medicare has shown growth in net sales and total assets from March 2019 to March 2025, increasing from INR 183.75 crore to INR 405.51 crore in sales. However, profitability has declined, with profit after tax dropping from INR 61.54 crore in March 2022 to INR 23.90 crore in March 2025.

Answer:<BR>The historical performance of Themis Medicare shows a fluctuating trend in key financial metrics over the years, with notable changes in revenue, profit, and expenses.<BR><BR>Breakdown:<BR>Themis Medicare's net sales have generally increased from INR 183.75 crore in March 2019 to INR 405.51 crore in March 2025, despite a dip in March 2022. Total operating income followed a similar pattern, reaching INR 405.51 crore in March 2025. However, total expenditure has also risen, amounting to INR 356.46 crore in March 2025, which includes significant costs such as raw materials and employee expenses. Operating profit, excluding other income, has fluctuated, peaking at INR 95.63 crore in March 2022 before declining to INR 49.05 crore in March 2025. Profit before tax showed a decline from INR 83.92 crore in March 2022 to INR 33.74 crore in March 2025, while profit after tax also decreased from INR 61.54 crore to INR 23.90 crore in the same period. The company's total assets grew from INR 345.34 crore in March 2020 to INR 588.03 crore in March 2025, with total liabilities increasing from INR 345.34 crore to INR 588.03 crore as well. Cash flow from operating activities improved to INR 34 crore in March 2025, although the net cash outflow was recorded at INR 3 crore. Overall, Themis Medicare has experienced growth in sales and assets, but profitability has faced challenges in recent years.

Is Themis Medicare technically bullish or bearish?

As of November 25, 2025, the technical trend has shifted to a bearish stance, supported by daily moving averages and weekly Bollinger Bands, despite some short-term bullish signals from the KST.

As of 25 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the daily moving averages showing bearish momentum and the weekly Bollinger Bands confirming a bearish trend. The MACD on a monthly basis is also bearish, while the weekly KST is mildly bullish, indicating some divergence in shorter time frames. Overall, the bearish sentiment is reinforced by the significant negative returns over the past month and year, contrasting sharply with the broader market performance.

Are Themis Medicare Ltd latest results good or bad?

Themis Medicare Ltd's latest results are concerning, showing a 33.35% year-on-year decline in net sales and an operating loss of ₹3.62 crores, indicating serious financial difficulties and a bleak outlook. The stock has also dropped 57.62% over the past year, significantly underperforming the market.

The latest results for Themis Medicare Ltd are quite concerning. In the second quarter of FY26, the company reported a significant decline in net sales, which fell by 33.35% year-on-year to ₹77.99 crores. This decline is compounded by a 20.08% drop compared to the previous quarter. Additionally, the company experienced operating losses, with operating margins turning negative at -3.97%, a stark contrast to the healthy 14.64% margin recorded in the same quarter last year.<BR><BR>The net profit for the quarter was a loss of ₹3.62 crores, representing a staggering 125.33% decline year-on-year. Over the first half of FY26, Themis Medicare has accumulated losses of ₹17.84 crores, compared to profits of ₹38.97 crores in the first half of FY25, indicating deeper operational challenges rather than temporary setbacks.<BR><BR>The stock has also underperformed dramatically, with a 57.62% decline over the past year, significantly lagging behind the Sensex's 8.59% gain. Overall, these results suggest that Themis Medicare is facing serious financial difficulties, and the outlook appears bleak without a clear turnaround strategy.

Should I buy, sell or hold Themis Medicare Ltd?

Why is Themis Medicare Ltd falling/rising?

As of 09-May, Themis Medicare Ltd's stock price is declining at 97.96, down 0.86% and underperforming its sector. The stock has seen a significant drop in delivery volume and mixed performance relative to moving averages, indicating reduced investor participation and a continued downward trend.

As of 09-May, Themis Medicare Ltd's stock price is falling, currently at 97.96, reflecting a change of -0.85 (-0.86%). The stock has underperformed its sector by -1.35% today and has been on a consecutive decline for the last two days, resulting in a total drop of -2.07% during this period. Additionally, the stock's delivery volume has decreased significantly, with a 29.45% drop compared to the 5-day average, indicating falling investor participation. Although the stock is trading higher than its 20-day, 50-day, and 100-day moving averages, it is lower than its 5-day and 200-day moving averages, suggesting mixed performance trends. Overall, these factors contribute to the current downward movement in Themis Medicare Ltd's stock price.

Which are the latest news on Themis Medicare?